Galmed Pharmaceuticals Ltd. (GLMD)
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General